Monte Rosa Therapeutics (GLUE) Restructuring Costs (2024 - 2026)

Monte Rosa Therapeutics' Restructuring Costs history runs 3 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• On a quarterly basis, Restructuring Costs rose 22.89% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $35.7 million, a 15.13% increase from a year earlier, with the FY2025 full-year figure at $33.9 million, up 14.3% from the prior year.
• Restructuring Costs rose to $10.1 million in Q1 2026 per GLUE's latest filing, from $9.2 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $10.1 million in Q1 2026 and bottomed at $6.8 million in Q1 2024.
• The 3-year median for Restructuring Costs is $7.8 million (2025), against an average of $8.2 million.
• Across the five-year window, Restructuring Costs increased 2.99% in 2025 and rose 22.89% in 2026, its largest moves.
• Year by year, Restructuring Costs stood at $7.7 million in 2024, then increased by 18.95% to $9.2 million in 2025, then climbed by 9.74% to $10.1 million in 2026.
• Per Business Quant, the three latest GLUE Restructuring Costs figures stand at $10.1 million (Q1 2026), $9.2 million (Q4 2025), and $8.6 million (Q3 2025).